MX2019005253A - Formas cristalinas de analogos de sofosbuvir antiviral. - Google Patents

Formas cristalinas de analogos de sofosbuvir antiviral.

Info

Publication number
MX2019005253A
MX2019005253A MX2019005253A MX2019005253A MX2019005253A MX 2019005253 A MX2019005253 A MX 2019005253A MX 2019005253 A MX2019005253 A MX 2019005253A MX 2019005253 A MX2019005253 A MX 2019005253A MX 2019005253 A MX2019005253 A MX 2019005253A
Authority
MX
Mexico
Prior art keywords
sofosbuvir
antiviral
analogues
crystalline forms
compound
Prior art date
Application number
MX2019005253A
Other languages
English (en)
Inventor
Shi Bing
Zia Vahid
Wang Fang
Jean Casteel Melissa
Dashner Kathleen
Jung Hyuk-Jun
Sik Seo Mun
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005253(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of MX2019005253A publication Critical patent/MX2019005253A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente invención se describen las formas sólidas cristalinas de 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropiri midin-1(2H)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-iI)me toxi)(fenoxi)fosforilamino)propanoato de (S)-isopropilo (Compuesto I). Asimismo se proporcionan los procesos de fabricación y los métodos de uso de las formas cristalinas.
MX2019005253A 2013-12-23 2016-06-23 Formas cristalinas de analogos de sofosbuvir antiviral. MX2019005253A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920371P 2013-12-23 2013-12-23

Publications (1)

Publication Number Publication Date
MX2019005253A true MX2019005253A (es) 2019-08-05

Family

ID=52146765

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016008453A MX2016008453A (es) 2013-12-23 2014-12-08 Formas cristalinas de analogos de sofosbuvir antiviral.
MX2019005253A MX2019005253A (es) 2013-12-23 2016-06-23 Formas cristalinas de analogos de sofosbuvir antiviral.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016008453A MX2016008453A (es) 2013-12-23 2014-12-08 Formas cristalinas de analogos de sofosbuvir antiviral.

Country Status (27)

Country Link
US (1) US9340568B2 (es)
EP (1) EP3086795A1 (es)
JP (1) JP2017503015A (es)
KR (1) KR20160099710A (es)
CN (1) CN105873593A (es)
AP (1) AP2016009254A0 (es)
AR (1) AR098929A1 (es)
AU (1) AU2014370299B2 (es)
BR (1) BR112016013714A8 (es)
CA (1) CA2934799A1 (es)
CL (1) CL2016001509A1 (es)
CR (1) CR20160288A (es)
CU (1) CU20160096A7 (es)
DO (1) DOP2016000141A (es)
EA (1) EA201691029A1 (es)
HK (1) HK1222334A1 (es)
IL (1) IL246066A0 (es)
MD (1) MD20160087A2 (es)
MX (2) MX2016008453A (es)
MY (1) MY178102A (es)
PE (1) PE20160750A1 (es)
PH (2) PH12019500372A1 (es)
SG (1) SG11201604818SA (es)
TW (1) TW201609785A (es)
UY (1) UY35917A (es)
WO (1) WO2015099989A1 (es)
ZA (1) ZA201604345B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
CA2988393C (en) 2014-06-13 2023-08-22 Ratiopharm Gmbh Solid state forms of sofosbuvir
WO2016023906A1 (en) * 2014-08-13 2016-02-18 Sandoz Ag A crystalline form of sofosbuvir
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
WO2016156512A1 (en) * 2015-04-01 2016-10-06 Sandoz Ag A process for preparing a crystalline form of sofosbuvir
WO2017023716A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
WO2017023714A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
US20180228827A1 (en) * 2015-08-04 2018-08-16 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
WO2017029408A1 (en) * 2015-08-20 2017-02-23 Ratiopharm Gmbh Solid state forms of sofosbuvir
EP3430023A1 (en) 2016-03-17 2019-01-23 Mylan Laboratories, Limited Polymorphic forms of sofosbuvir
CZ2016257A3 (cs) 2016-05-05 2017-11-15 Zentiva, K.S. Amorfní forma sofosbuviru, způsob její přípravy a její stabilizace
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
CN109843900A (zh) 2016-08-19 2019-06-04 桑多斯股份公司 治疗丙型肝炎的索非布韦衍生物
CN108084237A (zh) * 2016-11-23 2018-05-29 广东东阳光药业有限公司 索非布韦的一水合物及其制备方法
CA3041420A1 (en) * 2016-12-22 2018-06-28 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Solid form of 4'-thio-2'-fluoronucleoside phosphamide compound and preparation method therefor and use thereof
RU2656228C9 (ru) * 2017-06-13 2019-04-16 Олег Ростиславович Михайлов Слабозакристаллизованная β-модификация (S)-изопропил 2-((S)-(((2R,3R,4R,5R)-5-(2,4-диоксо-3,4-дигидропиримидин-(2Н)-ил)-4-фтор-3-гидрокси-4-метилтетрагидрофуран-2-ил)метокси)-(фенокси)фосфориламино)пропаноата, способ её получения и фармацевтическая композиция на её основе
EP3661944A1 (en) 2017-08-03 2020-06-10 Sandoz AG Sofosbuvir hydrate
KR102248165B1 (ko) 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN109517018B (zh) * 2018-12-29 2021-05-04 石药集团中奇制药技术（石家庄）有限公司 一种索磷布韦新晶型及其制备方法
RU2745293C1 (ru) * 2019-12-26 2021-03-23 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения кристаллической формы 8 софосбувира (варианты)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AP3622A (en) 2009-05-13 2016-03-02 Gilead Sciences Inc Antiviral compounds
US8618076B2 (en) * 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
JP2013527145A (ja) * 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
CA2795062A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
US10034893B2 (en) * 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives

Also Published As

Publication number Publication date
CA2934799A1 (en) 2015-07-02
BR112016013714A2 (pt) 2017-08-08
MX2016008453A (es) 2016-10-14
UY35917A (es) 2015-05-29
AR098929A1 (es) 2016-06-22
MD20160087A2 (ro) 2016-12-31
KR20160099710A (ko) 2016-08-22
EP3086795A1 (en) 2016-11-02
TW201609785A (zh) 2016-03-16
HK1222334A1 (zh) 2017-06-30
US20150175646A1 (en) 2015-06-25
IL246066A0 (en) 2016-07-31
AU2014370299A1 (en) 2016-06-23
JP2017503015A (ja) 2017-01-26
CR20160288A (es) 2016-08-31
AP2016009254A0 (en) 2016-06-30
EA201691029A1 (ru) 2017-01-30
PH12016501203B1 (en) 2016-08-15
BR112016013714A8 (pt) 2020-05-26
CL2016001509A1 (es) 2016-12-02
SG11201604818SA (en) 2016-07-28
MY178102A (en) 2020-10-02
WO2015099989A1 (en) 2015-07-02
CU20160096A7 (es) 2016-11-29
US9340568B2 (en) 2016-05-17
PH12019500372A1 (en) 2020-03-02
ZA201604345B (en) 2017-11-29
AU2014370299B2 (en) 2017-11-30
CN105873593A (zh) 2016-08-17
PE20160750A1 (es) 2016-07-27
PH12016501203A1 (en) 2016-08-15
DOP2016000141A (es) 2016-07-15

Similar Documents

Publication Publication Date Title
MX2019005253A (es) Formas cristalinas de analogos de sofosbuvir antiviral.
HK1251578A1 (zh) 含結晶(s)-異丙基 2-(((s)-(((2r，3r，4r，5r)-5-(2，4-二氧代-3，4-二氫嘧啶-1(2h)-基)-4-氟-3-羥基-4-甲基四氫呋喃-2-基)甲氧基)(苯氧基)磷酰基)氨基)丙酸酯的片劑
PH12015502799A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
WO2015001504A3 (en) Antibody formulations and methods
PL3290428T3 (pl) Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
MX2018001073A (es) Nucleosidos de pirrolopirimidina y analogos de los mismos utiles como agentes antivirales.
PH12015502588A1 (en) 4`-fluoro-2`-methyl substituted nucleoside derivatives
MX2017011386A (es) NUCLEÓTIDOS DE PURINA ß-D-2'-DEOXI-2'A-FLUORO-2'-ß-C-SUSTITUIDOS-2 - MODIFICADOS-N6- SUSTITUIDOS PARA EL TRATAMIENTO DEL VIRUS DE LA HEPATITIS C.
MX365313B (es) Composición farmacéutica oral que comprende a,a,a-trifluorotimidin a y clorhidrato de 5-cloro-6-(2-iminopirrolidina-1-il)metil-2,4(1h ,3h)-pirimidina diona.
MX355885B (es) Composición farmacéutica de administración oral.
SG11201509427RA (en) 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives
MX2016005174A (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
MX2019006783A (es) Procedimiento para la preparacion de 4-amino-1-( (1s, 4r, 5s) -2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirim idin-2-ona.
GB201111779D0 (en) Chemical compounds
UA89386U (ru) Фармацевтическая композиция с противоишемическим и антигипертензивным действием
ME02294B (me) Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2 ,4-dioks0-3,4-dihidropirimidin-1-(2h)-il )-4 - fluor0-3-hidroksi-4-metiltetrahidrofuran-2- il)metoksi)(fenoksi)fosforil)amino)propanoat
CL2011000717A1 (es) Compuesto derivado de fosforamidato de nucleosido de purina, un hidrato o solvato del mismo; composicion que lo comprende; proceso de preparacion, util para el tratamiento de la infeccion por el virus de la hepatitis c (vhc).